MADRIGAL PHARMACEUTICALS, INC. financial data

Symbol
MDGL on Nasdaq
Location
West Conshohocken, PA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 19 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 430% % -41%
Quick Ratio 25% % 185%
Debt-to-equity 76% % 132%
Return On Equity -44% % 24%
Return On Assets -25% % 43%
Operating Margin -31% % 89%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 22,939,969 shares
Common Stock, Shares, Outstanding 22,842,073 shares 3.8%
Entity Public Float $5,600,000,000 USD 9.8%
Common Stock, Value, Issued $2,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 22,434,310 shares 5.5%
Weighted Average Number of Shares Outstanding, Diluted 22,434,310 shares 5.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $137,250,000 USD
Revenue from Contract with Customer, Excluding Assessed Tax $958,403,000 USD 432%
Operating Income (Loss) $300,097,000 USD 40%
Net Income (Loss) Attributable to Parent $288,284,000 USD 38%
Earnings Per Share, Basic -12.85 USD/shares 41%
Earnings Per Share, Diluted -12.85 USD/shares 41%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $198,693,000 USD 99%
Cash, Cash Equivalents, and Short-term Investments $1,114,749,000 USD 11%
Accounts Receivable, after Allowance for Credit Loss, Current $134,476,000 USD 150%
Inventory, Net $74,841,000 USD 120%
Assets, Current $1,245,770,000 USD 21%
Property, Plant and Equipment, Net $1,499,000 USD -32%
Operating Lease, Right-of-Use Asset $4,939,000 USD 106%
Assets $1,259,589,000 USD 21%
Accounts Payable, Current $48,878,000 USD 12%
Employee-related Liabilities, Current $69,211,000 USD 102%
Accrued Liabilities, Current $260,392,000 USD 109%
Liabilities, Current $310,288,000 USD 83%
Operating Lease, Liability, Noncurrent $6,731,000 USD 561%
Liabilities $656,900,000 USD 128%
Accumulated Other Comprehensive Income (Loss), Net of Tax $873,000 USD 87%
Retained Earnings (Accumulated Deficit) $2,090,466,000 USD -16%
Stockholders' Equity Attributable to Parent $602,689,000 USD -20%
Liabilities and Equity $1,259,589,000 USD 21%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $88,891,000 USD 40%
Net Cash Provided by (Used in) Financing Activities $8,640,000 USD -98%
Net Cash Provided by (Used in) Investing Activities $163,878,000 USD 67%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 22,842,073 shares 3.8%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $83,627,000 USD -84%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $203,783,000 USD 94%
Deferred Tax Assets, Valuation Allowance $591,049,000 USD 16%
Deferred Tax Assets, Gross $591,411,000 USD 16%
Operating Lease, Liability $7,749,000 USD 287%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $287,879,000 USD 38%
Lessee, Operating Lease, Liability, to be Paid $10,282,000 USD 363%
Operating Lease, Liability, Current $1,018,000 USD 3.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,065,000 USD 93%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,242,000 USD 8%
Operating Lease, Weighted Average Discount Rate, Percent 0.1004 pure -5.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2,533,000 USD 1046%
Lessee, Operating Lease, Liability, to be Paid, Year Three $2,102,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $214,427,000 USD 76%
Preferred Stock, Shares Issued 2,369,797 shares 0%
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $12,058,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $2,140,000 USD
Preferred Stock, Shares Outstanding 2,369,797 shares 0%
Depreciation, Depletion and Amortization $379,000 USD 126%
Deferred Tax Assets, Net of Valuation Allowance $362,000 USD 67%
Share-based Payment Arrangement, Expense $98,130,000 USD 23%
Interest Expense $3,297,000 USD -14%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%